Skip to content
InMed-logo-01
  • Science
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • IntegraSyn™ Cannabinoid Manufacturing
    • InMed’s Research of Rare Cannabinoids
  • Investor
  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Governance
    • Partners and Collaborators
    • Events Calendar
    • Careers
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
  • Contact
Menu
  • Science
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • IntegraSyn™ Cannabinoid Manufacturing
    • InMed’s Research of Rare Cannabinoids
  • Investor
  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Governance
    • Partners and Collaborators
    • Events Calendar
    • Careers
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
  • Contact
TSX_Logo
NASDAQ_Logo

Articles and Videos

June 8, 2020
Cannabinol 101: The Science of Cannabinol (CBN)
Cannabinol, or CBN for short, is one of the more than 100 rare cannabinoids found in the Cannabis plant. CBN is found in aged Cannabis...
Read More
May 27, 2020
InMed’s cannabinol (CBN) formulation for glaucoma – Executive Interview with CEO Eric A. Adams
In this video, InMed Pharmaceuticals CEO Eric A. Adams speaks about the company’s ocular disease program. INM-088 is a cannabinol (CBN) formulation showing potential to...
Source: Edison TV
Read More
May 11, 2020
InMed’s therapeutic development of cannabinol and update on programs – Executive Interview with CEO Eric A. Adams
In this video, InMed Pharmaceuticals' CEO Eric A. Adams speaks about the company’s therapeutic development of cannabinol (CBN), a rare cannabinoid showing potential to treat...
Source: Edison TV
Read More
May 11, 2020
InMed Pharmaceuticals leading the development of cannabinol CBN therapeutics – Executive Interview with CEO Eric A. Adams
InMed Pharmaceuticals is the first company to advance cannabinol (CBN) into clinical trials for therapeutic development. It has begun a Phase 1 clinical trial in...
Source: Edison TV
Read More
January 23, 2020
What is Cannabinol (CBN)? Four things to know about this rare cannabinoid.
What is cannabinol, or CBN? View this infographic to learn four things about cannabinol. Is cannabinol (CBN) psychoactive? How is cannabinol (CBN) different from THC...
Read More
January 21, 2020
InMed Shares Preclinical Data at 2020 EB World Congress
At the EB World Congress in London, UK, InMed's scientific team officially revealed CBN as the active pharmaceutical ingredient (API) in INM-755 while exhibiting preclinical...
Read More
1 2 3 … 5 Next »

Overview

Learn More

Board of Directors

Learn More

Scientific Advisory Board

Learn More

Investor Alerts

Sign up to receive news releases from InMed Pharmaceuticals.
Learn More
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4
Science
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • IntegraSyn™ Cannabinoid Manufacturing
  • InMed’s Research of Rare Cannabinoids

Investor

  • News Releases
  • Latest Presentation
  • Letter to Shareholders
  • SEDAR® Filings
  • Financial Reports
  • Sign up for Investor Alerts

About

  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Corporate Governance
  • Partners and Collaborators
  • Events Calendar
  • Careers

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2021 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On: